Skip to main content
OpenTrials
Completed

NCT Number: NCT04401384

Effectiveness of Acupuncture and Doxylamine/Pyridoxine for Moderate to Severe Nausea and Vomiting in Pregnancy

Nausea and vomiting in pregnancy (NVP) is one of the most common symptoms of pregnancy affecting 50-85% of women during the first half of pregnancy. Maternal morbidity is common and includes psychological effects, financial burden, clinical complications from nutritional deficiencies, gastrointestinal trauma, and in rare cases, neurological damage. As the main means of alternative treatment, economical and easy to obtain; the clinical efficacy of acupuncture treatment of this disease has low level of evidence and needs to be reconfirmed. Doxylamine vitamin B6 sustained release tablets (Diclectin, combination of doxylamine succinate (10mg) and pyridoxine hydrochloride (10mg) are The American College of Obstetricians and Gynecologists recommends with Level A evidence the use of vitamin B6 in combination with doxylamine as first-line pharmacotherapy for treatment of NVP. The efficacy and safety of Diclectin has been confirmed in many years of research, but there is no evidence of high-level evidence-based medicine for the Chinese population. The purpose of this multicenter, randomized, double-blind, placebo-controlled trial was to investigate the efficacy and safety of acupuncture versus Diclectin in the treatment of NVP. We hypothesis that: (1)Sham acupuncture and Diclectin (Arm B) is more effective than sham acupuncture and placebo (Arm D); (2)Active acupuncture and placebo (Arm C) is more effective than sham acupuncture and placebo (Arm D); (3) There is no interaction (either synergistic or antagonistic effects) between the two interventions of active acupuncture and Diclectin in patients with NVP.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

First Affiliated Hospital of Heilongjiang Chinese Medicine University, Harbin, Heilongjiang, China

Loading trial locations.

About this study

Subjects will be randomized into one of the four treatment arms: A) active acupuncture (30 min /every day) + Diclectin (combination of doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg) , 2-4 tablets/day); B) sham acupuncture (30 min /every day) + Diclectin (2-4 tablets/day); C) active acupuncture (30 min / every day) + Diclectin placebo (2-4 tablets/day); D) sham acupuncture (30 min /every day) + Diclectin placebo (2-4 tablets/day). Participants will receive active acupuncture or sham acupuncture treatment daily, 14 times in total, and receive Diclectin or placebo treatment every day (2 tablets at bedtime for the first two days, if the symptoms are unrelieved, add one tablet in the morning, if the symptoms are still unrelieved, add another one tablet at three o 'clock in the afternoon) for 2 consecutive weeks, 28-56 tablets in total. Daily measurement PUQE score, Visual analog scale (VAS), Adverse events and concomitant medications. Weekly visits will include global assessment of well being, adverse events and concomitant medications. The visit after treatment will assess NVP quality of life (NVPQoL), SAS, SDS and so on. Participants will be followed up 30 days after treatment. Primary outcomes is difference of the mean change in PUQE score from baseline to the last visit. Secondary outcomes were some core outcome set for hyperemesis gravidarum, including weight difference, quality of life (change in Global assessment of well-being, NVPQOL, VAS, SDS and SAS), pregnancy complication, treatment compliance, neonatal outcomes; area under the curve of PUQE score, effect of intervention on PUQE score reduction over treatment period and adverse events.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women with 20-45 years of age;
  • PUQE score ≥6;
  • 7-14 weeks of gestation with viable fetus inside the uterine cavity confirmed by ultrasound dating;
  • Less than 20% weight loss.

Exclusion criteria

  • Having major medical problems such as malignant tumor, acute or subacute severe hepatitis, severe aplastic anemia, idiopathic thrombocytopenic purpura, acute appendicitis, acute pancreatitis, TORCH syndrome, etc
  • Having chronic medical conditions such as poorly controlled diabetes, coronary heart disease, uncontrolled hypertension, etc
  • Coexistence of other diseases that cause vomiting such as infectious disease, gestational trophoblastic disease, etc
  • Having asthma, increased intraocular pressure, narrow-angle glaucoma, narrow peptic ulcer, pyloric obstruction, bladder neck obstruction, etc
  • Taking antiemetics such as vitamin B6, ondansetron, metoclopramide, prednisone, anti-vomiting Chinese medicine, etc., within the past week
  • Receiving conservative treatment such as dietary and lifestyle modification
  • Abnormal physical examination and laboratory tests (minor abnormalities in laboratory tests due to pregnancy vomiting, such as liver function and ions, are acceptable for inclusion)
  • Having mental handicaps or psychological disorders
  • Allergic to doxylamine, other ethanolamine-derived antihistamines, pyridoxine hydrochloride, or any inactive ingredient in diclectin
  • Using monoamine oxidase inhibitors
  • Driving or operating heavy machinery
  • Using alcohol or other central nervous system inhibitors

Treatment and study plan

Diclectin

Drug

Diclectin (combination of 10 mg doxylamine and 10 mg pyridoxine hydrochloride in a delayed release tablet) During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of Diclectin or placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.

Diclectin placebo

Drug

Diclectin placebo will be packed and tested by a commercial pharmacy supply company specifically for this study. It have the same appearance, size, batch, odor, and taste compared with Diclectin. During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.

Active acupuncture

Device

Participants will receive active acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).

Sham acupuncture

Device

Blunt-tipped placebo needles will be used. Participants will receive sham acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6). Then, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).

Primary outcomes

  1. Score change of pregnancy unique quantification of emesis (PUQE) scale from baseline to day 15

    Time frame: Baseline to day 15; Scores ranged 3 to 15, with higher scores indicating more

    Score change of pregnancy unique quantification of emesis (PUQE) scale from baseline to day 15

Secondary outcomes

  1. Score change of maternal weight from baseline to the last visit

    Time frame: Baseline to day 15; no range of variation

    Score change of maternal weight from baseline to the last visit

  2. Change of electrolyte index (sodium)

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: mmol/L

  3. Change of electrolyte index (potassium)

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: mmol/L

  4. Change of electrolyte index (calcium)

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: mmol/L

  5. Change of electrolyte index (chlorine)

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: mmol/L

  6. Change of electrolyte index (phosphorus)

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: mmol/L

  7. Change of electrolyte index (magnesium)

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: mmol/L

  8. Change of electrolyte index (iron)

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: μmol/L

  9. Change of electrolyte index (zinc)

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: μmol/L

  10. Change of AST

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: U/L

  11. Change of ALT

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: U/L

  12. Change of ALP

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: U/L

  13. Change of creatinine

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: μmol/L

  14. Change of urea

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: mmol/L

  15. Change of TSH

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: mIU/L

  16. Change of free triiodothyronine

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: pmol/L

  17. Change of free thyroxine

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: pmol/L

  18. Change of vitamin b1

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: ng/ml

  19. Change of vitamin b6

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: ng/ml

  20. Change of vitamin b12

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: ng/ml

  21. Change of cortisol

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: ug/dL

  22. Change of ghrelin

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: ng/ml

  23. Change of leptin

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: ng/ml

  24. Change of 5-hydroxytryptamine

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: ng/ml

  25. Change of substance P

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: pg/ml

  26. Change of arginine vasopressin plasma

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: pg/ml

  27. Change of GDF 15

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: pg/ml

  28. Change of IGFBP 7

    Time frame: Baseline to day 15

    Value changes from baseline to last Visit. Unit: ng/ml

  29. Intravenous fluid treatment during treatment

    Time frame: Baseline to day 15

    Intravenous fluid treatment during treatment

  30. Concomitant treatment

    Time frame: Baseline to day 15

    Concomitant treatment

  31. Hospital admission during treatment

    Time frame: Baseline to day 15

    Hospital admission during treatment

  32. Termination of pregnancy

    Time frame: Data collected from baseline to the end of follow-up period (four weeks after the end of treatment).

    Termination of pregnancy. If the patient is suffering further aggravation of hyperemesis gravidarum, the termination of a wanted pregnancy will be done due to life in danger. Or congenital anomalies are found by ultrasound, the termination of a wanted pregnancy will be done.

  33. Maternal outcomes

    Time frame: Data collected from baseline to 42 days after postpartum.

    Including pregnancy complications, termination of pregnancy and birth outcomes. Pregnancy complications including miscarriage (in the first trimester and in the second trimester), hypertensive disorders, and gestational diabetes; birth outcomes including live birth, vaginal delivery, cesarean section, gestational age, preterm, birth weight and small for gestational age.

  34. Patient satisfaction with treatment

    Time frame: Baseline to day 15

    Such as loss of confidence or intolerance to daily acupuncture and so on

  35. Treatment compliance

    Time frame: Baseline to day 15

    Such as the percentage of drug or needle used; or drug tablets or acupuncture sessions.

  36. Offspring outcomes

    Time frame: Data collected from baseline to to 42 days after postpartum.

    Including fetal and neonatal congenital anomalies, fetal and neonatal mortality, neonatal hypoglycemia and NICU admission.

  37. Area under the curve (AUC) of PUQE score over treatment

    Time frame: Baseline to day 15

    Scores ranged 3 to 15, with higher scores indicating more severe NVP

  38. PUQE score reduction based on different TCM patterns

    Time frame: Scores ranged 3 to 15, with higher reduction indicating the better

    PUQE score reduction based on different TCM patterns

  39. Adverse events and serious adverse events

    Time frame: Baseline to the end of follow-up (four weeks after the end of treatment)

    The percentage of adverse events and serious adverse events

  40. Quality of life: NVPQoL

    Time frame: Baseline to day 15

    Range 30-210, high being poor QoL

  41. Quality of life: VAS

    Time frame: Baseline to day 15

    Ranged 0-10, high being more severe symptoms

  42. Quality of life: SDS

    Time frame: Baseline to day 15

    Range 25-10, high being more severe

  43. Quality of life: SAS

    Time frame: Baseline to day 15

    Range 25-100, high being more severe

  44. Quality of life: global assessment of well-being

    Time frame: Baseline to day 15

    Range 0-10, low being more severe

  45. PUQE score reduction at different levels of NVP

    Time frame: Scores ranged 3 to 15, with higher reduction indicating the better

    PUQE score reduction at different levels of NVP

Sponsors and collaborators

Lead sponsor

Xiaoke Wu

Other

Collaborators

  • Affiliated Hospital of Jiamusi Medical University
  • First Affiliated Hospital of Heilongjiang Chinese Medicine University
  • Hegang Maternal and Child Health Hospital
  • Heilongjiang Provicial Hospital
  • Jiamusi Maternal and Child Health Hospital
  • Jiangxi Maternal and Child Health Hospital
  • Jixi Maternal and Child Health Hospital
  • Luoyang Hospital of TCM
  • Mudanjaing Maternal and Child Health Hospital
  • Ningxia Hui Autonomous Region Hospital of TCM
  • Shuangyashan Maternal and Child Health Hospital
  • Suihua Maternal and Child Health Hospital
  • Xuzhou Central Hospital

Registry information

Official study title

Effectiveness of Acupuncture and Doxylamine/Pyridoxine for Moderate to Severe Nausea and Vomiting in Pregnancy: A Randomized Controlled Two-by-two Factorial Trial

Important dates

Study start
2020
Primary completion
2021
Study completion
2022
First posted
May 26, 2020
Registry last updated
Apr 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.